ساخت فرمولاسیون لیپوزومی حاوی پاکلی تاکسل و مقایسه سمیت آن با پاکلی تاکسل لیپوزومه نشده بر رده‌ی سلولی MCF-7 سرطان پستان

نویسندگان
المیرا ربانی 1
رودابه بهزادی 2
محمد مجدی زاده 3
بی بی فاطمه حقیرالسادات 4
1 کارشناسی ارشد ژنتیک، گروه زیست شناسی، دانشگاه آزاد اسلامی واحد تهران مرکز، تهران، ایران.
2 استادیار، گروه زیست شناسی، دانشگاه آزاد اسلامی واحد تهران مرکز، تهران، ایران.
3 کارشناسی ارشد زیست شناسی سلولی و مولکولی، گروه زیست فناوری، شرکت ریز زیست فناوران فردا نگر، پارک علم و فناوری یزد، ایران.
4 استادیار، مرکز تحقیقات نانوتکنولوژی پزشکی و مهندسی بافت، پژوهشکده علوم تولید مثل ، دانشگاه علوم پزشکی شهید صدوقی یزد، ایران.
10.52547/jmj.18.2.26
چکیده
مقدمه: شیمی درمانی یکی از روش های رایج در درمان سرطان است که همواره با چالش هایی روبرو بوده است. هدف از پژوهش حاضر ساخت نانوحامل های حاوی داروی شیمی درمانی پاکلی تاکسل و بررسی سمیت آن بر رده سلولی MCF-7 سرطان پستان بود.
روش کار: سه فرمولاسیون از نانو حامل های لیپوزومی حاوی پاکلی تاکسل با غلظت های متفاوتی از فسفاتیدیل کولین و کلسترول با استفاده از روش فیلم لایه نازک ساخته شد. سپس با توجه به میزان بارگذاری دارو، یکی از فرمولاسیون ها انتخاب و پگیله شد. درصد بارگذاری دارو درون نانولیپوزوم پگیله، الگوی رهایش دارو در شرایط سلول سالم و سرطانی، اندازه و بار سطحی نانو ذرات با استفاده از DLS و شکل ظاهری نانو ذرات با استفاده از میکروسکوپ پویش الکترونیکی بررسی شد. در پایان سمیت سامانه لیپوزومی حاوی دارو و داروی لیپوزومه نشده بر رده سلولیMCF-7 با استفاده از روشMTT  مورد بررسی قرار گرفت.
یافته­ ها: درصد بارگذاری دارو، اندازه، پتانسیل زتا نانو حامل های پگیله شده حاوی دارو به ترتیب 2.35±90.6 درصد، nm 49.4 و mV 46.74±5.55- بود. رهایش دارو از سامانه لیپوزومی طی 72 ساعت در شرایط سلول سالم و سرطانی آهسته بود. شکل ظاهری نانو ذرات صاف و کروی بوده و هیچ برهم کنش شیمیایی میان دارو و نانو حامل مشاهده نشد. همچنین داروی پاکلی تاکسل لیپوزومه در مقایسه با داروی لیپوزومه نشده سمیت بیشتری روی رده سلولی MCF-7 سرطان پستان داشت.
نتیجه­­ گیری: با توجه به برخورداری از ویژگی های فیزیکوشیمیایی مناسب، فرمولاسیون لیپوزومی حاصل از مطالعه حاضر را می توان برای انجام پژوهش های بیشتر در زمینه سرطان پستان پیشنهاد کرد.
کلیدواژه‌ها
لیپوزوم
پاکلی تاکسل
سلول های MCF-7
سرطان
شیمی درمانی

عنوان مقاله English

Fabrication of liposomal formulation containing paclitaxel and comparison of its toxicity with non-liposomal paclitaxel on MCF-7 breast cancer cell line

نویسندگان English

Elmira Rabani 1
Roudabeh Behzadi 2
Mohammad Majdizadeh 3
Bibi Fatemeh Haghiralsadat 4
1 MSc. Department of Biology, Islamic Azad University Central Tehran Branch, Tehran, Iran
2 Assistant Professor, Department of Biology, Islamic Azad University Central Tehran Branch, Tehran, Iran
3 MSc. Nano-Biotech Foresight Company Biotechnology Campus, Science & Technology Park of Yazd, Yazd, Iran
4 Assistant Professor, Medical nanotechnology & tissue engineering research center, Yazd reproductive sciences institute, Shahid Sadoughi University of medical sciences, Yazd, Iran
چکیده English

Introduction: Chemotherapy is one of the most common methods in cancer therapy that has always faced challenges.
The aim of the present study was to develop nano-carriers containing paclitaxel chemotherapy drug and to investigate its toxicity on MCF-7 breast cancer cell line.
Materials and Methods: Three formulations of liposomal nano-carriers containing paclitaxel with different concentrations of phosphatidylcholine and cholesterol were fabricated using the thin film method. Then according to the loading rate of drug, one of the formulations was selected and pegylated. Percentage of drug loading into pegylated nano-liposomes, drug release pattern in healthy and cancerous cell conditions, size and surface charge of nanoparticles (using DLS) and morphology of nanoparticles (using SEM) was evaluated. At the end, the toxicity of liposomal system containing drug and non-liposome drug on MCF-7 cell line was evaluated by MTT assay.
Result: The results showed that drug loading percentage, size, zeta potential of pegylated nano-carriers containing the drug were 90.6±2.35%, 49.4nm and -46.74±5.55mV, respectively. Release of the drug from the liposomal system is slow within 72 hours in normal and cancerous cell conditions. The morphology of the nanoparticles was smooth and spherical, and no chemical interaction was observed between the drug and the nano-carrier. Paclitaxel liposomal also had more toxicity to MCF-7 cell line breast cancer than non-liposomal drug.
Conclusion: Based on the results, the liposomal formulation of this study can be recommended for further research
in breast cancer with respect to its physicochemical properties.

کلیدواژه‌ها English

Liposome
Paclitaxel
MCF-7 cells
Neoplasm
chemotherapy
1. Parsa N. Molecular and Cellular Basis of Human Cancer. Journal of Cell & Tissue. 2012; 2(4): 365-376 2. Hadavand-Mirzaei Z, Irani S, Atyabi F. Comparison of cytotoxicity of chitosan- docetaxel nanoparticles and docetaxel anticancer drug on MDA-MB-231 breast cancer cells. Razi Journal of Medical Sciences. 2016; 23(144): 1-18. 3. Pecorino Lauren. Molecular biology of cancer mechanism, targets and therapeuticsy. 3th ed. United Kingdom: Oxford University Press; 2012: 4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2010; 68(1): 7-30. 5. Radmard AR. Five common cancers in Iran. Arch Iran Med 2010; 13: 143-6. 6. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol 2009; 20(3): 556-63. 7. Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M. Paclitaxel and its evolving role in the management of ovarian cancer. BioMed research international. 2015; 2015(1): 1-21. 8. Rasaneh S, Salehi-Zahabi S. The effect of chitosan nanoparticles containing paclitaxel on destruction of breast cancer cells. Journal of Clinical Research in Paramedical Sciences.2016; 4(4): 311-17. 9. Priyadarshini K, Keerthi AU. Paclitaxel against cancer: a short review. Med chem. 2012; 2(7):139-41. 10. Barbuti A, Chen ZS. Paclitaxel through the ages of anticancer therapy: exploring its role in chemoresistance and radiation therapy. Cancers. 2015; 7(4):2360-71. 11. Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014; 25(18):2677-81. 12. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Annals of oncology: official journal of the European Society for Medical Oncology. 1994; 5:S3-6. 13. Yari Khosroshahi A, Habibi Khaniani B, Naghdibadi H. Review on taxol as the most important anticancer natural drug. JMP. 2006; 2 (18): 1-10 14. Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D, Anto RJ. Sensitization of Taxol-Induced Apoptosis by Curcumin Involves Down-Regulation of Nuclear Factor-KappaB and the Serine/Threonine Kinase Akt and is Independent of Tubulin Polymerization. J Biol Chem. 2005; 280(8):6301-8. 15. Koohi Moftakhari Esfahani M, Alavi S E, Heidarinasab A, Chiani M, akbarzadeh A. Making paclitaxel nanoliposomal and evaluating its effect on the MCF-7. NCMBJ. 2013; 3 (10) :67-71 16. Mohanraj VJ, Chen Y. Nanoparticles-a review. Tropical journal of pharmaceutical research. 2006; 5(1):561-73. 17. Hoseinizadeh MJ. An overview of the most important mechanisms and systems of targeted drug delivery.Scientific research applied biology. 2016; 6(21): 17-28 18. Majdizadeh M, Rezaei Zarchi S, Movahedpour AA, Shahi Malmir H, Sasani E, Haghiralsadat BF. A new strategy in improving therapeutic indexes of medicinal herbs: preparation and characterization of nano-liposomes containing Mentha piperita essential oil. SSU_Journals. 2018 Feb 15;25(11):853-64. 19. Shahi Malmir H, Kalantar SM, Sasani E, Asgari M, Majdizadeh M, Haghiralsadat BF. Synthesis and optimization of niosomal carriers containing doxorubicin in order to achieve a final formulation with high potential in cancer cells temperature and acidity. SSU_Journals. 2019 Jan 15;26(10):879-94. 20. Sasani E, Shahi Malmir H, Daneshmand F, Majdizadeh M, Haghiralsadat BF. A new study on synthesize and optimization of PEGylated LipoNiosomal nanocarriers containing curcumin for use in cancer chemotherapy. SSU_Journals. 2018 Oct 15;26(6):528-41. 21. Haghiralsadat F, Amoabediny G, Sheikhha MH, Zandieh‐doulabi B, Naderinezhad S, Helder MN, Forouzanfar T. New liposomal doxorubicin nanoformulation for osteosarcoma: drug release kinetic study based on thermo and pH sensitivity. Chemical biology & drug design. 2017 Sep;90(3):368-79. 22. Ghanbarzadeh B, Pezeshky A, Hamishehkar H, Moghadam M. Vitamin A palimitate-loaded nanoliposomes: study of particle size, zeta potential, efficiency and stability of encapsulation. Iranian Food Science and Technology Research Journal. 2016; 12(2): 261-75. 23. Ohvo-Rekilä H, Ramstedt B, Leppimäki P, Slotte JP. Cholesterol interactions with phospholipids in membranes. Progress in lipid research. 2002 Jan 1;41(1):66-97. 24. Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems-a review (Part 2). Tropical Journal of Pharmaceutical Research. 2013;12(2):265-73. 25. Zhao W, Song Zhuang X-RQ. Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes. International journal of nanomedicine. Dove Press; 2011;6:3087. 26. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release. Elsevier; 2010;148(2):135–46. 27. Rasoulian-broujeni M, Najafi S, Hojati-emami S, Dehghan mohammad mehdi. Preparation and evaluation of nanoparticles containing oxaliplatin for target drug release at the site of breast tumor. Iran J Breast Dis. 2011;4(3):33–43. 28. Alavi SE, Koohi-moftakhar-esfahani M, Akbarzadeh A. Evaluating the effect of nanoliposomal hydroxyurea urea on the breast cancer cell line. New Cellular & Molecular Biotechnology Journal. 2013; 3: 63–7. 29. Fang Y, Wu X, Chen J, Dang S, Jiang D, Chen M, et al. Preparation and Characterization of mPEG Modified Magnetic Long-Circulating Doxorubicin Hydrochloride Liposomes. Adv Mater Res. 2013; 661:87–90. 30. Alyane M, Barratt G, Lahouel M. Remote loading of doxorubicin into liposomes by transmembrane pH gradient to reduce toxicity toward H9c2 cells. SAUDI Pharm J. 2016; 24(2):165–75. 31. Haghiralsadat BF, Amouabedini G, Sheikhha MH, Mohammadnezhad MJ, Nadernezhad S, Malaei-balasi Z, et al. New Approach for the Synthesis, Entrapment of Hydrophilic Drugs and Evaluation of Physico-Chemical Characteristics of PH-sensitive Nano-Liposome: Improving Therapeutic Efficacy of Doxorubicin in Order to Treatment Bone Tumor and Reducing the Side Effects. J Shaeed Sdoughi Univ Med Sci Yazd. 2016; 24(10):780–9. 32. Haghiralsadat F, Amoabediny G, Sheikhha MH, Zandieh-doulabi B, Naderinezhad S, Helder MN, et al. New liposomal doxorubicin nanoformulation for osteosarcoma: Drug release kinetic study based on thermo and pH sensitivity. Chem Biol Drug Des. 2017; 90(3):368–79. 33. Naderinezhad S, Haghiralsadat BF, Amouabedini G, Naderinezhad A, Esmaeili Z, Akbaezadeh A. Synthesis of biodegradable and self-assembled anionic nano –carrier: Novel approach for improvement of Curcumin- delivery to bone tumors cells & Mathematical modeling of drug-release kinetic. New Cell Mol Biotechnol J. 2017; 7(27):77–84. 34. Shirzad M, Jamehbozorgi S, Aghabozorg H, Akbarzadeh A. Drug Delivery of Pegylated Nanoliposomal Cisplatin in Ovarian Cancer Cell Line A2780CP: in vitro Study. Vol. 7, New Cellular & Molecular Biotechnology Journal. 2017; 7: 77–84. 35. Haghiralsadat BF, Amouabedini G, Naderinezhad S, Sheikhha MH, Malaei-balasi Z, Akbarzadeh A, et al. An evaluation of the transmembrane ammonium sulfate gradients method in lipid system to improve trapping capacity of amphipathic weak. New Cell Mol Biotechnol J. 2017;7(28):49–60 36. Naderinezhad S, Amouabedini G, Haghiralsadat F. Co-delivery of hydrophilic and hydrophobic anticancer drugs using biocompatible pH-sensitive lipid-based nano-carriers for multidrug-resistant cancers. RSC Adv. 2017; 7(1):30008–19. 37. Haghiralsadat BF, Nadernezhad S, Amoabediny G, Montazeri F, Zandieh-doulabi B. effects of surface charge on cytotoxicity of liposomal Doxorubicin on bone cancer cell line. Daneshvar Med. 2018; 25(133):19–26. 38. Bahrami-Banan F, Hasan Sheikhha M, Ghasemi N, Majdizadeh M, Haghiralsadat BF. Preparation and Study of Nano-Niosomes Containing Doxorubicin and Evaluation of its Toxicity on Acute Myeloblastic Leukemia Cell Line KG-1. Journal of Payavard Salamat. 2018 Nov 15;12(4):